aTyr Pharma/$ATYR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About aTyr Pharma
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Ticker
$ATYR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
61
ISIN
US0021202025
Website
aTyr Pharma Metrics
BasicAdvanced
$472M
-
-$0.80
0.79
-
Price and volume
Market cap
$472M
Beta
0.79
52-week high
$5.98
52-week low
$1.48
Average daily volume
3.3M
Financial strength
Current ratio
7.795
Quick ratio
7.239
Long term debt to equity
15.629
Total debt to equity
17.352
Profitability
EBITDA (TTM)
-66.354
Management effectiveness
Return on assets (TTM)
-39.82%
Return on equity (TTM)
-79.70%
Valuation
Price to book
6.29
Price to tangible book (TTM)
6.29
Price to free cash flow (TTM)
-6.762
Free cash flow yield (TTM)
-14.79%
Free cash flow per share (TTM)
-78.38%
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-11.62%
3-year earnings per share growth (CAGR)
-22.59%
10-year earnings per share growth (CAGR)
-46.80%
What the Analysts think about aTyr Pharma
Analyst ratings (Buy, Hold, Sell) for aTyr Pharma stock.
Bulls say / Bears say
aTyr Pharma's lead therapeutic candidate, efzofitimod, is advancing through a Phase 3 clinical trial for pulmonary sarcoidosis, with additional trials underway for other interstitial lung diseases (ILDs), indicating strong potential for groundbreaking therapeutic developments. (directorstalkinterviews.com)
Analysts have given aTyr Pharma a consensus rating of 'Strong Buy' with an average price target of $20.2, suggesting a potential upside of approximately 280.41% from the current stock price. (stockanalysis.com)
The company's strategic partnership with Kyorin Pharmaceutical Co., Ltd. for the Japanese market underscores its international outreach and the potential for significant revenue streams upon market approval of its treatments. (directorstalkinterviews.com)
aTyr Pharma reported a net margin of -98.46% as of September 30, 2024, indicating significant financial losses and raising concerns about its profitability. (fintel.io)
The company's gross margin stood at -84.73% as of September 30, 2024, reflecting high costs relative to revenue and potential challenges in achieving sustainable profitability. (fintel.io)
With a return on equity of -79.70% and a free cash flow of -$37.33 million, aTyr Pharma's financial metrics highlight the risks associated with its current operational performance. (directorstalkinterviews.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
aTyr Pharma Financial Performance
Revenues and expenses
aTyr Pharma Earnings Performance
Company profitability
aTyr Pharma News
AllArticlesVideos
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
GlobeNewsWire·2 weeks ago
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
GlobeNewsWire·1 month ago
aTyr Pharma to Present at Upcoming Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for aTyr Pharma stock?
aTyr Pharma (ATYR) has a market cap of $472M as of July 08, 2025.
What is the P/E ratio for aTyr Pharma stock?
The price to earnings (P/E) ratio for aTyr Pharma (ATYR) stock is 0 as of July 08, 2025.
Does aTyr Pharma stock pay dividends?
No, aTyr Pharma (ATYR) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next aTyr Pharma dividend payment date?
aTyr Pharma (ATYR) stock does not pay dividends to its shareholders.
What is the beta indicator for aTyr Pharma?
aTyr Pharma (ATYR) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.